Viral Vectors And Plasmid DNA Manufacturing Market Size Report, 2023-2032
The global viral vectors and plasmid DNA manufacturing market size was exhibited at USD 3.32 billion in 2022 and is projected to hit around USD 13.09 billion by 2032, growing at a CAGR of 14.72% during the forecast period 2023 to 2032.
Key Pointers:
Viral Vectors And Plasmid DNA Manufacturing Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 3.8 Billion |
|
Market Size by 2032 |
USD 13.09 Billion |
|
Growth Rate from 2023 to 2032 |
CAGR of 14.72% |
|
Base year |
2022 |
|
Forecast period |
2023 to 2032 |
|
Segments covered |
Vector type, workflow, application, end-use, disease, product type, region |
|
Regional scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
Viral vectors are tools for delivering genetic material into cells. Viruses have developed specific systems for transporting their DNA inside the cells they infect. Furthermore, retrovirus, adenovirus, lentivirus, herpes simplex virus, and others are among the viral vectors which can be employed to transfer genetic material into the genetic composition of cells.
The viral vectors and plasmid DNA manufacturing market saw a lucrative opportunity due to the COVID-19 pandemic. Furthermore, the market players are shifting their business focus toward the development of viral vectors for the SARS-CoV-2 vaccine. Viral vectors are commonly employed tools used in the discovery and development of vaccines against SARS-CoV-2. The ongoing COVID-19 pandemic has encouraged investment in this space in search of a vaccine as viral vector-based vaccines can be manufactured and designed relatively quickly with the use of the same building blocks. For instance, Companies such as Johnson and Johnson/Janssen (J&J); AstraZeneca/University of Oxford; Gamaleya Research Institute; and CanSino Biologics have developed viral vector-based vaccines.
The market for viral vectors and plasmid DNA manufacturing is growing due to the increasing prevalence of target ailments and diseases and the efficacy of viral vectors in gene therapy delivery. This increase is aided by continued research into viral vector-based cell and gene therapies, as well as financing for gene therapy advancement. In addition, an increase in the number of gene therapy-based discovery programs initiated by biotechnology and pharmaceutical companies is expected to drive the demand for scalable production of gene therapy vectors.
A rising number of patients opting for gene therapy is driving the global market. Due to a surge in gene therapy development, demand for plasmid DNA is skyrocketing. Thus, Adeno-associated virus (AAV), lentivirus, and other viral vector systems require pDNA (Plasmid DNA) to be manufactured. In addition, several genetic illnesses and infectious diseases are on the rise in different areas of the globe. For instance, as per UNAIDS data, 38.0 million people across the globe were living with HIV in 2019, and 1.7 million people were newly infected with the virus.
Additionally, rising demand for synthetic genes and untapped expanding market potential are projected to open up new chances for market players in the future. However, the risk of insertional mutagenesis and the high cost of gene treatments stymie market expansion. Furthermore, technical innovations that address the constraints posed by traditional vector production processes create an attractive potential for industry manufacturers.
Some of the prominent players in the Viral Vectors And Plasmid DNA Manufacturing Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Viral Vectors And Plasmid DNA Manufacturing market.
By Vector Type
By Workflow
By Application
By End-use
By Disease
By Product Type
By Region
Chapter 1. Executive Summary
1.1. Market Summary
Chapter 2. Research Methodology
2.1. Information Procurement
2.2. Information Or Data Analysis
2.3. Market Model
2.3.1. Market Analysis, By Vector Type
2.3.1.1. By Characteristics/Advantage & Disadvantage
2.3.1.2. By Clinical Trials
2.3.1.3. By Manufacturing Service Penetration/Availability
2.3.2. Market Study, By End-Use
2.3.3. Regional Analysis
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation & Scope
3.2. Market Dynamics
3.2.1. Market Drivers Analysis
3.2.1.1. Robust Pipeline For Gene Therapies And Viral Vector Vaccines
3.2.1.2. Technological Advancemnets In Manufacturing Vectors
3.2.1.3. Highly Competitive Market And Various Strategies Undertaken By Market Entities
3.2.2. Market Restraint Analysis
3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy And Viral Vectors
3.2.3. Market Challenge Analysis
3.2.3.1. Production Capacity Challenges
3.2.3.2. Manufacturing Challenges Pertaining To Large Scale Production Of Vectors
3.2.4. Market Opportunity Analysis
3.2.4.1. Facility Expansion For Cell And Gene Therapies
3.3. Covid-19 Impact
3.4. Viral Vector Production: Stepwise Challenges & Solutions
3.4.1. Host Cell Production & Banking Needs
3.4.2. Viral Vector Production, F&F: Challenges & Solutions
3.4.3. Viral Vector Production, Analytics: Challenges & Solutions
3.5. Penetration & Growth Prospect Mapping For Vector Type, 2023
3.6. Industry Analysis - Porter’s Five Forces
3.7. Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.8. Penetration & Growth Prospect Mapping For Prominent Industry Players, 2023
3.9. Manufacturer’s Landscape
3.10. Viral Vector Production Capacity Mapping Analysis
3.10.1. North America: Capacity & Service Mapping
3.10.2. Europe: Capacity & Service Mapping
3.10.2.1. Cobra Biologics (Sweden And The U.K.)
3.10.2.2. Biovian (Finland)
3.10.2.3. Oxford Biomedica (U.K.)
3.10.2.4. Lonza Pharma & Biotech (The Netherlands)
3.10.2.5. Finvector Oy (Finland)
3.10.2.6. Fujifilm Diosynth Biotechnologies (Denmark)
3.10.2.7. Fujifilm Diosynth Biotechnologies (U.K.)
3.10.2.8. Catalent Inc. (Belgium)
3.10.2.9. Novasep (Belgium)
3.10.2.10. Exothera (Belgium)
3.10.2.11. Delphi Genetics Sa (Belgium)
3.10.2.12. Yposkesi (France)
3.10.2.13. Vivebiotech (Spain)
3.10.2.14. Molmed Spa (Italy)
3.10.2.15. Anemocyte (Italy)
3.11. List Of Companies With Portfolio Comprising Vector-Based Therapeutic Candidates
3.12. List Of Vector Manufacturers
Chapter 4. Viral Vector Production: Costs
4.1. Cost Models For Viral Vector Production
4.1.1. Campaign Model
4.1.2. Day Rate Model
4.1.3. Hybrid Model
4.2. Viral Vector Manufacturing Pricing Analysis
4.2.1. Parameters Affecting Price
4.2.2. Aav: Pricing Analysis
4.2.3. Lentivirus: Pricing Analysis
4.2.4. Adenovirus: Pricing Analysis
4.2.5. Retrovirus: Pricing Analysis
4.2.6. Plasmid: Pricing Analysis
4.2.7. Gene Synthesis Cost
4.2.8. Genes/ Gene Fragment Cost Analysis
Chapter 5. Viral Vector Production & Yield Analysis
5.1. Production Yields: Biomarin, Spark Therapeutics & Solid Biosciences
5.2. Various Modes Of Vector Production To Increase & Achieve Target Doses
5.2.1. Adenoviral Vectors
5.2.2. Gamma- Retroviral (Mlv – Murineleukemia Virus) Vectors
5.2.3. Lentiviral Vectors
5.2.4. Aav Vectors
5.2.5. Raav Vectors
5.2.5.1. Raav Production: Challenges & Solutions
5.3. Total Vector Quantity Produced Per Day And Yield Volume Using Different Cell Culture Systems
5.4. Measures Undertaken To Optimize Manufacturing Of Viral Vectors For Cell And Gene Therapy
5.5. Analysis Of Large- And Small-Scale Production Of Viral Vectors Based On Batch Size
5.5.1. Small-Scale/Laboratory-Scale Cell Culture Systems
5.5.2. Large-Scale Cell Culture Systems
5.6. Common Practices For Small-Scale (10–50l) Adenovirus Vector Manufacturing
Chapter 6. Viral Vector Manufacturing: Process Economic Considerations & Challenges
6.1. Technological Advances In Manufacturing
6.1.1. Stable Producer Cell Lines
6.1.2. Transient Production
6.1.3. Lentiviral Vector Production Process
6.1.3.1. Developments In Lentivector Platform
6.2. Cogs Analysis Of The Baseline Process
6.2.1. Raw Material
6.2.2. Labor Costs
6.2.3. Process Costs
6.3. Regulatory Expectations
6.4. Approaches For Viral Vector Supply Gene Therapy
6.4.1. Gene Therapy Manufacturing Facilities: Trends & Types
6.4.2. Gene Therapy Road Map: Key External Trends
Chapter 7. Viral Vector Manufacturing Market: Strategic Alliances
7.1. Is The Time Right To Invest In Gene Therapy Sector?
7.2. Strategic Approaches For Market Scale-Up
7.2.1. Partnership Models
7.2.2. Acquisition
7.2.3. Minority Interest (Ownership)
7.2.4. Joint Venture
7.2.5. Alliance
7.2.6. Franchise
7.3. Collaborations In Viral Vector Manufacturing Market
7.3.1. Breakthrough Growth: Lonza, Oxford Biomedica & Others
Chapter 8. Vector Type Business Analysis
8.1. Viral Vector & Plasmid Dna Manufacturing Market: Vector Type Movement Analysis
8.2. Adenovirus
8.2.1. Global Adenovirus Market 2020 - 2032
8.3. Retrovirus
8.3.1. Global Retrovirus Market 2020 - 2032
8.4. Adeno-Associated Virus (Aav)
8.4.1. Aav Manufacturing: Operating Cros & Cmos/Cdmos
8.4.2. Global Aav Market 2020 - 2032
8.5. Lentivirus
8.5.1. Global Lentivirus Market 2020 - 2032
8.6. Plasmids
8.6.1. Global Plasmids Market 2020 - 2032
8.7. Others
8.7.1. Global Other Vectors Market 2020 - 2032
Chapter 9. Workflow Business Analysis
9.1. Viral Vector & Plasmid Dna Manufacturing Market: Workflow Movement Analysis
9.2. Upstream Manufacturing
9.2.1. Global Upstream Manufacturing Market Estimates And Forecast 2020 - 2032
9.2.2. Vector Amplification And Expansion
9.2.2.1. Global Vector Amplification And Expansion Market Estimates And Forecast 2020 - 2032
9.2.3. Vector Recovery/Harvesting
9.2.3.1. Global Vector Recovery/Harvesting Market Estimates And Forecast 2020 - 2032
9.3. Downstream Manufacturing
9.3.1. Global Downstream Manufacturing Market Estimates And Forecast, For 2020 - 2032
9.3.2. Purification
9.3.2.1. Global Purification Market Estimates And Forecast 2020 - 2032
9.3.3. Fill Finish
9.3.3.1. Global Fill Finish Market Estimates And Forecast 2020 - 2032
Chapter 10. Application Business Analysis
10.1. Viral Vector & Plasmid Dna Manufacturing Market: Application Movement Analysis
10.2. Antisense & Rnai Therapy
10.2.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Antisense, & Rnai Therapy 2020 - 2032
10.3. Gene Therapy
10.3.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Gene Therapy 2020 - 2032
10.4. Cell Therapy
10.4.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Cell Therapy 2020 - 2032
10.5. Vaccinology
10.5.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Vaccinology 2020 - 2032
10.6. Research Applications
10.6.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Research Applications 2020 - 2032
Chapter 11. End-Use Business Analysis
11.1. Viral Vector & Plasmid Dna Manufacturing Market: End-Use Movement Analysis
11.2. Pharmaceutical And Biopharmaceutical Companies
11.2.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Pharmaceutical And Biopharmaceutical Companies 2020 - 2032
11.3. Research Institutes
11.3.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Research Institutes 2020 - 2032
Chapter 12. Disease Business Analysis
12.1. Viral Vector & Plasmid Dna Manufacturing Market: Disease Movement Analysis
12.2. Cancer
12.2.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Cancer 2020 - 2032
12.3. Genetic Disorders
12.3.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Genetic Disorders 2020 - 2032
12.4. Infectious Diseases
12.4.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Infectious Diseases 2020 - 2032
12.5. Other Diseases
12.5.1 Global Viral Vector & Plasmid Dna Manufacturing Market For Other Diseases, 2020 - 2032
Chapter 13 Product Type Business Analysis
13.1 Viral Vector & Plasmid DNA Manufacturing Market: Product Type Movement Analysis
13.2 Plasmid DNA
13.2.1 Global Viral Vector & Plasmid Dna Manufacturing Market For Plasmid Dna, 2020 - 2032
13.3 Viral Vector
13.3.1 Global Viral Vector & Plasmid Dna Manufacturing Market For Viral Vector, 2020 - 2032
13.4 Non-Viral Vector
13.4.1 Global Viral Vector & Plasmid Dna Manufacturing Market For Non-Viral Vector, 2020 - 2032
Chapter 14. Regional Business Analysis
14.1. Viral Vector & Plasmid Dna Manufacturing Market Share By Regional, 2023 & 2032
14.2. North America
14.2.1. North America Viral Vector & Plasmid Dna Manufacturing Market 2020 - 2032
14.2.2. U.S.
14.2.3. Canada
14.3. Europe
14.3.1. .Europe Viral Vector & Plasmid Dna Manufacturing Market 2020 - 2032
14.3.2. Germany
14.3.3 UK
14.3.4 France
14.3.5 Italy
14.3.6 Spain
14.4. Asia Pacific
14.4.1. Asia Pacific Viral Vector & Plasmid Dna Manufacturing Market 2020 - 2032
14.4.2. China
14.4.3 Japan
14.4.4 India
14.4.5 South Korea
14.4.6 Australia
14.5. Latin America
14.5.1 Latin America Viral Vector & Plasmid Dna Manufacturing Market, 2020 - 2032
14.5.2 Brazil
14.5.3 Mexico
14.5.4 Argentina
14.6. Middle East Africa
14.6.1. Mea Viral Vector & Plasmid Dna Manufacturing Market 2020 - 2032
14.6.2 South Africa
14.6.3 Saudi Arabia
14.6.4 UAE
Chapter 15. Competitive Analysis
15.1. Recent Developments & Impact Analysis, By Key Market Participants
15.2. Company/Competition Categorization
15.3. Manufacturer’s Landscape
15.3.1. Distribution By Location Of Manufacturing Facility
15.3.2. Cdmos Operating In China
15.3.3. Distribution By Scale Of Production
15.3.4. Distribution By Location Of Manufacturing Facility, Type Of Organization, And Purpose Of Production
15.4. Vendor Landscape
15.4.1. List Of Key Technology Supplier
15.4.2. List Of Raw Material/Technology Distributors
15.4.2.1. Region-Wise Bioprocessing Technology Distributors:
15.5. Key Initiatives & Strategic Alliances Analysis
15.5.1. Merger & Acquisition Deals
15.5.2. Collaborations & Partnerships
15.5.3. Business Expansion
15.5.4. Technology Collaborations
15.6. Public Companies Analysis
15.6.1. Industry Players
15.6.1.1. Takara Bio Inc.
15.6.1.2. Fujifilm Diosynth Biotechnologies
15.6.1.3. Batavia Biosciences B.V.
15.6.2. Non-Industry Players
15.6.3. Synergy Analysis: Major Deals & Strategic Alliances
15.7. Private Companies
15.7.1. List Of Key Emerging Companies
15.7.2. Market Participation Categorization (Market Operations & Weakness)
15.7.3. Strategy Framework
15.8. Company Profiles: Contract Manufacturing Organizations (Cmos)
15.8.1. Merck Kgaa
15.8.1.1. Company Overview
15.8.1.2. Sigma-Aldrich Inc.
15.8.1.2.1. Company Overview
15.8.1.3. Financial Performance
15.8.1.4. Product Benchmarking
15.8.1.5. Swot Analysis
15.8.1.6. Operational Capacity
15.8.1.7. Strategic Initiatives
15.8.2. Lonza.
15.8.2.1. Company Overview
15.8.2.2. Financial Performance
15.8.2.3. Product Benchmarking
15.8.2.4. Swot Analysis
15.8.2.5. Operational Capacity
15.8.2.6. Srategic Initiatives
15.8.3. Fujifilm Diosynth Biotechnologies U.S.A., Inc.
15.8.3.1. Company Overview
15.8.3.2. Financial Performance
15.8.3.3. Product Benchmarking
15.8.3.4. Swot Analysis
15.8.3.5. Operational Capacity
15.8.3.6. Startegic Initiatives
15.8.4. Cobra Biologics Ltd.
15.8.4.1. Company Overview
15.8.4.2. Product Benchmarking
15.8.4.3. Swot Analysis
15.8.4.4. Operational Capacity
15.8.4.5. Strategic Initiatives
15.8.5. Thermofisher Scientific Inc.
15.8.5.1. Company Overview
15.8.5.2. Financial Performance
15.8.5.3. Product Benchmarking
15.8.5.4. Swot Analysis
15.8.5.5. Operational Capacity
15.8.5.6. Strategic Initiatives
15.8.6. Waisman Biomanufacturing
15.8.6.1. Company Overview
15.8.6.2. Product Benchmarking
15.8.6.3. Swot Analysis
15.8.6.4. Operational Capacity
15.8.6.5. Strategic Inititaives
15.8.7. Genezen Laboratories
15.8.7.1. Company Overview
15.8.7.2. Product Benchmarking
15.8.7.3. Swot Analysis
15.8.7.4. Operational Capacity
15.8.8. Yposkesi
15.8.8.1. Company Overview
15.8.8.2. Product Benchmarking
15.8.8.3. Swot Analysis
15.8.8.4. Operational Capacity
15.8.8.5. Strategic Initiaves
15.8.9. Advanced Bioscience Laboratories, Inc. (Abl Inc.)
15.8.9.1. Company Overview
15.8.9.2. Financial Performance
15.8.9.3. Product Benchmarking
15.8.9.4. Swot Analysis
15.8.9.5. Operational Capacity
15.8.9.6. Strategic Initiatives
15.8.10. Novasep Holding S.A.S.
15.8.10.1. Company Overview
15.8.10.2. Product Benchmarking
15.8.10.3. Swot Analysis
15.8.10.4. Operational Capacity
15.8.10.5. Strategic Initiatives
15.8.11. Orgenesis Biotech Israel Ltd (Formerly Atvio Biotech Ltd.)
15.8.11.1. Company Overview
15.8.11.2. Financial Performance
15.8.11.3. Product Benchmarking
15.8.11.4. Swot Analysis
15.8.11.5. Operational Capacity
15.8.11.6. Strategic Initiatives
15.8.12. Vigene Biosciences Inc.
15.8.12.1. Company Overview
15.8.12.2. Product Benchmarking
15.8.12.3. Swot Analysis
15.8.12.4. Operational Capacity
15.8.12.5. Startegic Initiatives
15.8.13. General Electric Company (Ge Healthcare).
15.8.13.1. Company Overview
15.8.13.2. Financial Performance
15.8.13.3. Product Benchmarking
15.8.13.4. Swot Analysis
15.8.13.5. Operational Capacity
15.8.13.6. Strategic Initiatives
15.8.14. Cevec. Pharmaceuticals Gmbh
15.8.14.1. Company Overview
15.8.14.2. Product Benchmarking
15.8.14.3. Swot Analysis
15.8.14.4. Operational Capacity
15.8.14.5. Strategic Initiatives
15.8.15. Batavia Biosciences B.V.
15.8.15.1. Company Overview
15.8.15.2. Product Benchmarking
15.8.15.3. Swot Analysis
15.8.15.4. Operational Capacity
15.8.15.5 Strategic Initiatives
15.8.16. Biovion Oy
15.8.16.1. Company Overview
15.8.16.2. Product Benchmarking
15.8.16.3. Swot Analysis
15.8.16.4. Operational Capacity
15.8.16.5. Strategic Initiatives
15.8.17. Wuxi Apptec Co., Ltd.
15.8.17.1. Company Overview
15.8.17.2. Financial Performance
15.8.17.3. Product Benchmarking
15.8.17.4. Swot Analysis
15.8.17.5. Operational Capacity
15.8.17.6. Strategic Initiatives
15.8.18. Vgxi, Inc.
15.8.18.1. Company Overview
15.8.18.2. Product Benchmarking
15.8.18.3. Swot Analysis
15.8.18.4. Operational Capacity
15.8.18.5. Strategic Initiatives5
15.8.19. Catalent Inc.
15.8.19.1. Company Overview
15.8.19.2. Paragon Bioservices Inc.
15.8.19.3. Company Overview
15.8.19.4. Financial Performance
15.8.19.5. Product Benchmarking
15.8.19.6. Swot Analysis
15.8.19.7. Operational Capacity
15.8.19.8. Strategic Initiatives
15.8.20. Miltenyi Biotec Gmbh
15.8.20.1. Company Overview
15.8.20.2. Lentigen Technology Inc.
15.8.20.3. Product Benchmarking
15.8.20.4. Swot Analysis
15.8.20.5. Operational Capacity
15.8.20.6. Strategic Initiatives
15.8.21. Sirion Biotech Gmbh.
15.8.21.1. Company Overview
15.8.21.2. Product Benchmarking
15.8.21.3. Swot Analysis
15.8.21.4. Operational Capacity
15.8.21.5. Strategic Initiatives
15.8.22. Virovek Incorporation
15.8.22.1. Company Overview
15.8.22.2. Product Benchmarking
15.8.22.3. Swot Analysis
15.8.22.4. Operational Capacity
15.8.22.5. Strategic Initiaitves
15.8.23. Biontech Imfs Gmbh
15.8.23.1. Company Overview
15.8.23.2. Product Benchmarking
15.8.23.3. Swot Analysis
15.8.23.4. Operational Capacity
15.8.24. Vivebiotech S.L.
15.8.24.1. Company Overview
15.8.24.2. Financial Performance
15.8.24.3. Product Benchmarking
15.8.24.4. Swot Analysis
15.8.24.5. Operational Capacity
15.8.24.6. Strategic Initiatives
15.8.25. Creative Biogene
15.8.25.1. Company Overview
15.8.25.2. Product Benchmarking
15.8.25.3. Swot Analysis
15.8.26. Vibalogics Gmbh
15.8.26.1. Company Overview
15.8.26.2. Product Benchmarking
15.8.26.3. Swot Analysis
15.8.26.4. Operational Capacity
15.8.26.5. Strategic Initiatives
15.8.27. Takara Bio Inc.
15.8.27.1. Company Overview
15.8.27.2. Financial Performance
15.8.27.3. Product Benchmarking
15.8.27.4. Swot Analysis
15.8.27.5. Operational Capacity
15.8.27.6. Strategic Initiaitves
15.9. Company Profiles: In-House Manufacturers
15.9.1. Cell And Gene Therapy Catapult
15.9.1.1. Company Overview
15.9.1.2. Product Benchmarking
15.9.1.3. Swot Analysis
15.9.1.4. Operational Capacity
15.9.1.5. Strategic Initiatives
15.9.2. Bluebird Bio Inc.
15.9.2.1. Company Overview
15.9.2.2. Financial Performance
15.9.2.3. Product Benchmarking
15.9.2.4. Swot Analysis
15.9.2.5. Operational Capacity
15.9.2.6. Strategic Initiatives
15.9.3. Addgene Inc.
15.9.3.1. Company Overview
15.9.3.2. Product Benchmarking
15.9.3.3. Swot Analysis
15.9.3.4. Operational Capacity
15.9.3.5. Strategic Initiatives
15.9.4. Aldevron Llc.
15.9.4.1. Company Overview
15.9.4.2. Product Benchmarking
15.9.4.3. Swot Analysis
15.9.4.4. Operational Capacity
15.9.4.5. Strategic Initiatives
15.9.5. Astellas Pharma, Inc.
15.9.5.1. Company Overview
15.9.5.2. Audentes Therapeutics
15.9.5.3. Company Overview
15.9.5.4. Financial Performance (Astellas Pharma Inc.)
15.9.5.5. Product Benchmarking
15.9.5.6. Swot Analysis
15.9.5.7. Operational Capacity
15.9.5.8. Strategic Initiatives
15.9.6. Biomarin Pharmaceutical, Inc.
15.9.6.1. Company Overview
15.9.6.2. Financial Performance
15.9.6.4. Swot Analysis
15.9.6.5. Operational Capacity
15.9.6.6. Strategic Initiatives
15.9.7. Regenxbio, Inc.
15.9.7.1. Company Overview
15.9.7.2. Financial Performance
15.9.7.3. Product Benchmarking
15.9.7.4. Swot Analysis
15.9.7.5. Operational Capacity
15.9.7.6. Strategic Initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers